tegafur has been researched along with bilirubin in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, K; Nose, H; Okada, S; Okazaki, N; Yoshimori, M | 1 |
| Arai, K; Honma, S; Iwasaki, Y; Kimura, Y; Takahashi, K; Takahashi, T; Yamaguchi, T | 1 |
| Akasu, T; Kodaira, S; Moriya, Y; Ohashi, Y; Shirao, K; Yoshida, S | 1 |
| Akaza, H; Fujimoto, H; Ikemoto, I; Kobayashi, M; Naito, S; Namiki, M; Tsukamoto, T; Usami, M | 1 |
| Aotani, E; Gemma, A; Hamano, T; Kobayashi, K; Takebayashi, T; Takeuchi, M | 1 |
| Asada, T; Fujiwara, M; Iizuka, A; Ishigure, K; Ishiyama, A; Ito, S; Kanda, M; Kobayashi, D; Kodera, Y; Matsushita, H; Mochizuki, Y; Murai, T; Murotani, K; Tanaka, C; Teramoto, H | 1 |
4 trial(s) available for tegafur and bilirubin
| Article | Year |
|---|---|
[Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Bilirubin; Drug Administration Schedule; Drug Combinations; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Postoperative Period; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Leukopenia; Lymph Node Excision; Male; Middle Aged; Neoplasm Staging; Pelvis; Rectal Neoplasms; Rectum; Survival Rate; Tegafur; Uracil | 2006 |
Efficacy of S-1 in patients with castration-resistant prostate cancer: a phase II study.
Topics: Adult; Aged; Alanine Transaminase; Androgen Antagonists; Anorexia; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Bilirubin; Body Surface Area; Dose-Response Relationship, Drug; Drug Combinations; Drug Tolerance; Humans; Lymphatic Metastasis; Male; Middle Aged; Orchiectomy; Oxonic Acid; Prostate-Specific Antigen; Prostatic Neoplasms; Safety; Tegafur; Treatment Outcome | 2010 |
Identification of adverse events that have a negative impact on quality of life in a clinical trial comparing docetaxel versus S-1 with cisplatin in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cognition Disorders; Docetaxel; Drug Combinations; Gastrointestinal Diseases; Humans; Lung Neoplasms; Oxonic Acid; Quality of Life; Taxoids; Tegafur | 2016 |
2 other study(ies) available for tegafur and bilirubin
| Article | Year |
|---|---|
Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy.
Topics: alpha-Fetoproteins; Analysis of Variance; Antineoplastic Agents; Ascites; Bilirubin; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Interferon-gamma; Liver Neoplasms; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Prognosis; Regression Analysis; Risk Factors; Serum Albumin; Tegafur; Time Factors | 1992 |
Proposal of a Scoring Scale to Estimate Risk of the Discontinuation of S-1 Adjuvant Monotherapy in Patients with Stage II to III Gastric Cancer: A Multi-Institutional Dataset Analysis.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Bilirubin; Blood Urea Nitrogen; Chemotherapy, Adjuvant; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Random Allocation; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; Serum Albumin; Stomach Neoplasms; Tegafur | 2019 |